“We continue to be greatly encouraged by these clinical results and the benefits this treatment offers to patients with GBM,” said Professor Krivoshapkin. “There is no standard approach on how to treat patients with recurrent GBM and the repeated use of EBRT in recurrent brain tumors is often limited by a relatively high risk of radiation toxicity. Intraoperative balloon electronic brachytherapy has the potential to deliver the required prescribed single focal dose that is equivalent to multiple sessions of EBRT while minimizing radiation dose to neighboring healthy tissue.”
iCAD recently assembled a panel of experts to expand research on Xoft Brain IORT to multiple leading cancer centers worldwide. The Company is also exploring other emerging applications for the Xoft System, including the treatment of early-stage rectal tumors.
The Xoft System is a 50 kV radiation oncology treatment solution that uses a miniaturized X-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site while minimizing risk of damage to healthy tissue in nearby areas of the body. The isotope-free radiation requires minimal shielding, enabling medical professionals to remain in the room during treatment.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.
Back to HCB News
